155 related articles for article (PubMed ID: 34729628)
1. Pilot-phase PET/CT study targeting integrin α
Nakamoto R; Ferri V; Duan H; Hatami N; Goel M; Rosenberg J; Kimura R; Wardak M; Haywood T; Kellow R; Shen B; Park W; Iagaru A; Gambhir SS
Eur J Nucl Med Mol Imaging; 2022 Dec; 50(1):184-193. PubMed ID: 34729628
[TBL] [Abstract][Full Text] [Related]
2. 18F-fluorobenzoate-labeled cystine knot peptides for PET imaging of integrin αvβ6.
Hackel BJ; Kimura RH; Miao Z; Liu H; Sathirachinda A; Cheng Z; Chin FT; Gambhir SS
J Nucl Med; 2013 Jul; 54(7):1101-5. PubMed ID: 23670900
[TBL] [Abstract][Full Text] [Related]
3.
Ren J; Zhu S; Zhang G; Tan X; Qiu L; Lin J; Jiang L
Mol Pharm; 2022 Jul; 19(7):2620-2628. PubMed ID: 35674464
[TBL] [Abstract][Full Text] [Related]
4. A Cystine Knot Peptide Targeting Integrin αvβ6 for Photoacoustic and Fluorescence Imaging of Tumors in Living Subjects.
Zhang C; Kimura R; Abou-Elkacem L; Levi J; Xu L; Gambhir SS
J Nucl Med; 2016 Oct; 57(10):1629-1634. PubMed ID: 27230926
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. A radiofluorinated divalent cystine knot peptide for tumor PET imaging.
Jiang L; Kimura RH; Ma X; Tu Y; Miao Z; Shen B; Chin FT; Shi H; Gambhir SS; Cheng Z
Mol Pharm; 2014 Nov; 11(11):3885-92. PubMed ID: 24717098
[TBL] [Abstract][Full Text] [Related]
7. Clinical Translation of a
Feng X; Wang Y; Lu D; Xu X; Zhou X; Zhang H; Zhang T; Zhu H; Yang Z; Wang F; Li N; Liu Z
J Nucl Med; 2020 Oct; 61(10):1461-1467. PubMed ID: 32086242
[TBL] [Abstract][Full Text] [Related]
8. Development and Preclinical Validation of a Cysteine Knottin Peptide Targeting Integrin αvβ6 for Near-infrared Fluorescent-guided Surgery in Pancreatic Cancer.
Tummers WS; Kimura RH; Abou-Elkacem L; Beinat C; Vahrmeijer AL; Swijnenburg RJ; Willmann JK; Gambhir SS
Clin Cancer Res; 2018 Apr; 24(7):1667-1676. PubMed ID: 29298796
[No Abstract] [Full Text] [Related]
9. Diagnostic accuracy of virtual 18F-FDG PET/CT bronchoscopy for the detection of lymph node metastases in non-small cell lung cancer patients.
Herbrik M; Treffert J; Geiger B; Riegger C; Hartung V; Rosenbaum-Krumme SJ; Forsting M; Antoch G; Heusner TA
J Nucl Med; 2011 Oct; 52(10):1520-5. PubMed ID: 21908390
[TBL] [Abstract][Full Text] [Related]
10. [
Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Dekervel J; Van Cutsem E; Verslype C; Van Laere K; Bormans G; Deroose CM
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3033-3046. PubMed ID: 32617641
[TBL] [Abstract][Full Text] [Related]
11. 99mTc-labeled cystine knot peptide targeting integrin αvβ6 for tumor SPECT imaging.
Zhu X; Li J; Hong Y; Kimura RH; Ma X; Liu H; Qin C; Hu X; Hayes TR; Benny P; Gambhir SS; Cheng Z
Mol Pharm; 2014 Apr; 11(4):1208-17. PubMed ID: 24524409
[TBL] [Abstract][Full Text] [Related]
12. A microdose clinical trial to evaluate [
Lee I; Lim I; Byun BH; Kim BI; Choi CW; Woo SK; Lee KC; Kang JH; Kil HS; Park C; Chi DY; Park J; Song K; Lim SM
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):95-102. PubMed ID: 32458006
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans.
Doss M; Kolb HC; Zhang JJ; Bélanger MJ; Stubbs JB; Stabin MG; Hostetler ED; Alpaugh RK; von Mehren M; Walsh JC; Haka M; Mocharla VP; Yu JQ
J Nucl Med; 2012 May; 53(5):787-95. PubMed ID: 22499613
[TBL] [Abstract][Full Text] [Related]
14. Biodistribution and radiation dosimetry in cancer patients of the ascorbic acid analogue 6-Deoxy-6-[
Long Y; Yi C; Wu R; Zhang Y; Zhang B; Shi X; Zhang X; Zha Z
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3072-3083. PubMed ID: 37191679
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution of the ¹⁸F-FPPRGD₂ PET radiopharmaceutical in cancer patients: an atlas of SUV measurements.
Minamimoto R; Jamali M; Barkhodari A; Mosci C; Mittra E; Shen B; Chin F; Gambhir SS; Iagaru A
Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1850-8. PubMed ID: 26062933
[TBL] [Abstract][Full Text] [Related]
16. (18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients.
Iagaru A; Mosci C; Shen B; Chin FT; Mittra E; Telli ML; Gambhir SS
Radiology; 2014 Nov; 273(2):549-59. PubMed ID: 25033190
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution, pharmacokinetics, dosimetry of [
Ballal S; Yadav MP; Moon ES; Kramer VS; Roesch F; Kumari S; Tripathi M; ArunRaj ST; Sarswat S; Bal C
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1915-1931. PubMed ID: 33244617
[TBL] [Abstract][Full Text] [Related]
18. PET/CT Imaging of NSCLC with a α
Flechsig P; Lindner T; Loktev A; Roesch S; Mier W; Sauter M; Meister M; Herold-Mende C; Haberkorn U; Altmann A
Mol Imaging Biol; 2019 Oct; 21(5):973-983. PubMed ID: 30671741
[TBL] [Abstract][Full Text] [Related]
19. A Microdose PET Study of the Safety, Immunogenicity, Biodistribution, and Radiation Dosimetry of
Keat N; Kenny J; Chen K; Onega M; Garman N; Slack RJ; Parker CA; Lumbers RT; Hallett W; Saleem A; Passchier J; Lukey PT
J Nucl Med Technol; 2018 Jun; 46(2):136-143. PubMed ID: 29438002
[TBL] [Abstract][Full Text] [Related]
20. Detecting Vulnerable Atherosclerotic Plaques by
Jiang L; Zhu H; Li Y; Wu X; Wang H; Cheng Z
Mol Pharm; 2019 Mar; 16(3):1350-1357. PubMed ID: 30742442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
